ScinoPharm Taiwan is recognized for its extensive technical capabilities and robust research and development (R&D) capacity, particularly in the field of active pharmaceutical ingredients (APIs) for cancer treatment. The company operates advanced cGMP production facilities that have successfully passed rigorous quality inspections from various global regulatory bodies, including the US FDA and the EU EMA. ScinoPharm specializes in the synthetic research and process development of drug candidates, focusing on high potency and oncological APIs for injectable formulations. Their commitment to quality is evident in their adherence to international cGMP standards, ensuring that all products are developed and manufactured with the utmost precision and safety.

In addition to its API manufacturing, ScinoPharm offers a comprehensive range of services, including contract research organization (CRO) and contract manufacturing organization (CMO) services, which are designed to support clients throughout the drug development process. The company has invested in innovative technologies, such as column chromatography for peptide purification and the Design of Experiment (DOE) tools to enhance manufacturing efficiency. Furthermore, ScinoPharm is actively engaged in biopharmaceutical development, having established its own cell line for protein drug production and collaborating on projects to develop biosimilars and advanced drug delivery systems. This strategic focus on innovation and quality positions ScinoPharm as a competitive player in the global pharmaceutical market.

China

Mainly supplying the international API market, ScinoPharm has become one of the leading international oncology generic APIs suppliers (in terms of generic APIs supply). In addition to anti-cancer APIs, we have also developed a wide variety of other products including CNS APIs, gastrointestinal APIs, etc.

ScinoPharm Taiwan

Company Details